
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
25 May 2022
Leukaemia UK reveals new strategy to go further than ever to stop leukaemia devastating lives
Leukaemia UK has revealed a new strategy to go further than ever to save and improve more lives, through research, awareness and advocacy.
3 February 2022
New analysis reveals the stark disparities in cancer rates between ethnic groups
The Cancer Research UK study demonstrates the importance of understanding the differences and inequalities in cancer and to highlight where improvements in survival, treatment and care can be made.
21 September 2022
A record year for Leukaemia UK London Marathon runners
62 runners put their best feet forward for Leukaemia UK A record 62 runners are taking part in this year’s London marathon to help fund vital research into leukaemia diagnosis,…
16 November 2021
Charities call on NHS to treat blood cancer equally in decision-making
The Blood Cancer Alliance undertook an evidence review to inform a new report exploring the unmet needs of people with blood cancer across the UK.